NEW
YORK, May 17, 2024 /PRNewswire/ -- Renal
Research Institute (RRI), a global leader in dialysis and
nephrology research and a subsidiary of Fresenius Medical Care AG,
today announced together with the Karolinska
Institutet a joint symposium, "Prevention of CKD
progression: the impact of new therapeutics." The Karolinska Institutet is one of the world's leading
medical universities.
Medical experts from across the globe will discuss clinical
trials, prescription practices, pharmaco-epidemiology and more
at this workshop in Stockholm
on May 22.
With chronic kidney disease (CKD) affecting about 1 in 10 adults
worldwide, new therapeutics have been developed to potentially
delay its progression. Notable among these are glucagon-like
peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose
cotransporter-2 inhibitors (SGLT2i).
"In the realm of chronic kidney disease management, GLP-1 RAs
and SGLT2is have shown promising results in clinical trials," said
Dr. Peter Kotanko, Head of
Biomedical and Evidence Generation and Research Director, Renal
Research Institute. "Our symposium aims to further advance the
conversation on the potential of these new therapeutics, bringing
together internationally recognized experts in diabetes, obesity,
kidney and cardiovascular medicine to pave the way for improving
patient care."
The symposium aims to explore these medications and their
potential impact on CKD progression in the light of the clinical
trials, bringing together global medical experts and fostering an
open dialogue to advance knowledge on the research through Q&A
sessions, while simultaneously providing a comprehensive overview
of the current landscape and future developments in the field
through specialized presentations from experts.
To learn more about RRI educational material and events,
including past symposiums, visit the RRI website at
https://renalresearch.com/education/.
About Peter Kotanko, MD,
FASN
Head of Biomedical Evidence Generation and
Research Director, Renal Research Institute Researcher
and scholar Dr. Peter Kotanko leads
RRI's scientists and fellows, heading the Institute's research
initiatives to improve patient outcomes and quality of life. His
prolific research career comprises more than 400 research papers,
book chapters, and scholarly works. With over 20 years of clinical
background and expertise in physiology, internal medicine, and
nephrology, Dr. Kotanko is an adjunct professor of medicine and
nephrology at the Icahn School of Medicine at Mount Sinai, New York. He is former vice chair
of the Department of Internal Medicine, Barmherzige BrĂ¼der Hospital
in Graz, Austria.
About Renal Research Institute (RRI)
Renal Research
Institute (RRI), a subsidiary of Fresenius Medical Care, achieves
its mission to improve the outcomes of patients with kidney disease
through research and innovation. RRI's highly developed and
specialized expertise in computational biomedicine, translational
clinical and biomedical research, and data analytics underscore the
Institute's track record of thinking outside the box and
identifying high-value areas. Through alliance and collaboration
agreements, RRI has forged strategic research relationships with
leading universities in the Americas, Asia, and Europe, fostering RRI's position at the
forefront of research activities in the field of dialysis and
nephrology.
For more information, visit the Renal Research Institute's
website at www.renalresearch.com.
About Fresenius Medical Care:
Fresenius Medical Care
is the world's leading provider of products and services for
individuals with renal diseases of which around 4.1 million
patients worldwide regularly undergo dialysis treatment. Through
its network of 3,862 dialysis clinics, Fresenius Medical Care
provides dialysis treatments for approx. 325,000 patients around
the globe. Fresenius Medical Care is also the leading provider of
dialysis products such as dialysis machines or dialyzers. Fresenius
Medical Care is listed on the Frankfurt Stock Exchange (FME) and on
the New York Stock Exchange (FMS).
Media Contact
Kirsten
Stratton
T +1 781 929 8096
kirsten.stratton@rriny.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/renal-research-institute-and-karolinska-institutet-announce-chronic-kidney-disease-management-symposium-highlighting-new-therapeutics-302149211.html
SOURCE Renal Research Institute